Life Sci AI | ​The Podcast | ​S4 Ep 2

Ep 2 | AI for New Drug Design

In the second episode of the series focusing on the use of AI in drug discovery, Nick is joined by the CSO of Iktos. Iktos are a French biotech for ligand-based and structure-based de novo drug design focusing on multi-parametric optimization. The very interesting episode delves into both the technology and also Quentin’s story and how Iktos has become a success story in the biotech space.

Quentin Perron is a medicinal chemist by training. He holds a PhD in organometallic chemistry from the University of Geneva. During his post-doc fellowship at UCLA he worked on the total synthesis of Brasillicardin A, a complex natural molecule known for having a potent immunosuppressive activity. After working as a medicinal chemist in CNS indications at Laboratoires Servier, he switched to data science and chemoinformatics at Quinten, a company specializing in data science services. In 2016, with his business partners Yann Gaston-Mathé and Nicolas Do Huu, he co-founded Iktos, a start-up company developing AI technologies for new drug design. He is now the CSO of the company.

​

​

To speak to Nick, please drop an email to n.mahoney@sciproglobal.com

Listen:
Apple > https://apple.co/3qvIgN2
Spotify > https://spoti.fi/3qvwQsW
Anchor > https://anchor.fm/scipro​